Search
Now showing items 1-10 of 153
Improving outcomes for the lung cancer patient with impaired lung function
(Institute of Cancer Research (University Of London), 2021-03-31)
Lung function impairment is common amongst patients with lung cancers. Identifying the patients that are most likely to benefit from anti-cancers therapies, without suffering significant toxicities, is central to improving ...
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.
(2021-05-12)
Purpose Effective treatment options are limited for patients with advanced (metastatic or unresectable) melanoma who progress after immune checkpoint inhibitors and targeted therapies. Adoptive cell therapy using ...
Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study.
(2021-10-06)
<h4>Purpose</h4>The effect of high-dose imatinib (800 mg/day) on survival in the adjuvant treatment of patients with resected KIT exon 9-mutated gastrointestinal stromal tumors (GIST) is not established. Here, the association ...
Extensive mucocutaneous, oesophageal and otic lichen planus secondary to nivolumab therapy.
(Wiley, 2021-03-01)
We report a 73-year-old female with metastatic renal cell carcinoma who developed a widespread lichenoid reaction following nivolumab treatment. The timeline of the reaction strongly correlated with the nivolumab treatment ...
Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.
(ELSEVIER SCI LTD, 2021-10-18)
BACKGROUND: In the phase III double-blind European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 trial, pembrolizumab improved recurrence-free and distant metastasis-free survival in patients with stage ...
Y disruption, autosomal hypomethylation and poor male lung cancer survival.
(2021-06-14)
Lung cancer is the most frequent cause of cancer death worldwide. It affects more men than women, and men generally have worse survival outcomes. We compared gene co-expression networks in affected and unaffected lung ...
Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma.
(2021-04-15)
Objective: Compare health-related quality of life (HRQoL) of selinexor versus placebo in patients with dedifferentiated liposarcoma. Materials & methods: HRQoL was assessed at baseline and day 1 of each cycle using the ...
First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts.
(ELSEVIER, 2021-01-15)
BACKGROUND: The treatment landscape of metastatic clear cell renal cell carcinoma (mccRCC) has been transformed by targeted therapies with tyrosine kinase inhibitors (TKI) and more recently by the incorporation of immune ...
Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial.
(ELSEVIER, 2021-04-23)
BACKGROUND: Among patients with advanced renal cell carcinoma (RCC), those with sarcomatoid histology (sRCC) have the poorest prognosis. This analysis assessed the efficacy of avelumab plus axitinib versus sunitinib in ...
A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma☆.
(ELSEVIER, 2021-02-06)
BACKGROUND: Approved first-line treatments for patients with BRAF V600-mutant advanced melanoma include nivolumab (a programmed cell death protein 1 inhibitor) plus ipilimumab (a cytotoxic T lymphocyte antigen-4 inhibitor; ...